• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

EPAD project participates at the EFPIA Rentrée 2017

2017-09-07News

On 7 September, the European Federation of Pharmaceutical Industries and Associations (EFPIA) held an event under the banner “Unlocking tomorrow’s cures” in Brussels, Belgium. The EFPIA Rentrée 2017 gathered six scientists working on groundbreaking, innovative and life-changing therapies:

  1. Dr Frank Bähner, Area Head Prophylactic Vaccines at Curevac, explained the advantages of mRNA vaccines where pandemics arise.
  2. Serge Van der Geyten (pictured), Director Neuroscience External Affairs at Janssen Pharmaceutical, presented EPAD with a talk entitled “Prevention of Alzheimer’s Dementia in Europe – the EPAD project”. He described the EPAD initiative, its aims and its progress to date.
  3. Alain Munafo, Global Head of Quantative Pharmacology at Merck explained the use of clinical trials in Multiple Sclerosis.
  4. Dr Alastair Coupe from Pfizer UK described the challenge of formulating better medicines for children.
  5. Ana Isabel Jiménez, Director of R&D at Sylentis, highlighted that oligonucleotides represent a novel approach to discovering new therapeutic agents.
  6. Luc Uylenbroeck, Head of New Patient Solutions and Portfolio Management at UCB, described how his company is able to create value for patients.

More information on the EFPIA Rentrée 2017: https://efpia.eu/news-events/the-efpia-view/blog-articles/07092017-efpia-s-rentree-2017-unlocking-tomorrow-s-cures/

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @RosetreesT workshop on neurodegenerative diseases. @craig_ritchie68 presented @IMI_EPAD & @AD_PREVENT (from 1:06:00). @brainhealthscot @AlzData youtu.be/PsAZ1T5MmBo twitter.com/brainhealthsco…

reply retweet favorite
8:01 am · 2021-03-04
Twitter
EPAD
EPAD
@IMI_EPAD

The latest @AlzheimerEurope #newsletter includes an article on the first local @IMI_EPAD community meeting held last month among the Scottish research sites and collaborators who have been involved in the EPAD Longitudinal Cohort Study. Read more here: bit.ly/Feb2021AEnews twitter.com/AlzheimerEurop…

reply retweet favorite
3:26 pm · 2021-03-03
Twitter
EPAD
EPAD
@IMI_EPAD

@AD_PREVENT @alzassociation @alzheimerssoc Congratulations to all the team 👏

reply retweet favorite
7:03 am · 2021-03-01
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.